Abstract
Objective:
This feasibility study was designed to evaluate the therapeutic potential of intraarterial urokinase combined with abciximab, an IV platelet glycoprotein IIb/IIIa receptor antagonist, in peripheral arterial thrombosis.
Conclusion:
The administration of a highly potent glycoprotein IIb/IIIa inhibitor in conjunction with intraarterial fibrinolysis was safe in 14 patients. One distal embolization and no major bleeding occurred. The primary success rate was 100%. Treatment times ranged from 50 min to 8 hr. We found a reocclusion rate of 7% (1/14) at intermediate follow-up.
MeSH terms
-
Abciximab
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Drug Therapy, Combination
-
Feasibility Studies
-
Female
-
Femoral Artery
-
Humans
-
Iliac Artery
-
Immunoglobulin Fab Fragments / administration & dosage
-
Immunoglobulin Fab Fragments / therapeutic use*
-
Infusions, Intra-Arterial
-
Infusions, Intravenous
-
Male
-
Middle Aged
-
Pilot Projects
-
Plasminogen Activators / administration & dosage
-
Plasminogen Activators / therapeutic use*
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Thrombolytic Therapy*
-
Thrombosis / drug therapy*
-
Urokinase-Type Plasminogen Activator / administration & dosage
-
Urokinase-Type Plasminogen Activator / therapeutic use*
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Plasminogen Activators
-
Urokinase-Type Plasminogen Activator
-
Abciximab